Lung cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• EGFR 300
• PD-L1 162
• PD-1 156
• KRAS 98
• ALK 72
• TP53 10
• HER2 63
• MET 43
• PI3K 1
• STAT3 0
• AKT 2
• ROS1 27
• mTOR 0
• VEGF 23
• BRAF 9
• RET 9
• NRF2 1
• MAPK 1
• ERK 0
• STING 0
• STK11 7
• YAP 1
• DLL3 27
• CTLA-4 15
• RAS 15
• CTNNB1 0
• TROP2 13
• JAK 1
• HIF-1 1
• AMPK 0
• PARP 2
• KEAP1 5
• JNK 0
• MYC 1
• B7-H3 14
• GPX4 0
• HER3 11
• PTEN 4
• MEK 1
• TIGIT 6
• FGFR 3
• IL-6 1
• PPAR 0
• EZH2 2
• HDAC 0
• PRMT5 7
• FAK 0
• COX-2 0
• HMGB1 0
• NTRK 5
• AXL 3
• BCL-2 0
• CDK4/6 4
• CXCR4 1
• CD47 1
• METTL3 0
• NLRP3 0
• SHP2 0
• HSP90 0
• MDM2 1

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Designing Programmable MOF-nanocomposites for Synergistic, Redox-Driven Antitumor Therapies (Photo-bioMOF)

  Fundacion IMDEA Energia· Mostoles Madrid, Spain· EU contribution €262,393· until Feb 2030· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Identifying and disrupting neuroimmune circuits in cancer (NeuroCAN)

  Universitat Basel· Basel, Switzerland· EU contribution €1,874,590· until Jun 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Predicting immunotherapy response in melanoma and non-small cell lung cancer patients using an extracellular vesicle-derived miRNA signature and a non-invasive CRISPR-based detection assay. (IT-PREDICT)

  Centre Georges-Francois Leclerc Association· Dijon, France· EU contribution €242,261· until Mar 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Dual Amplification Photoelectrochemical Platform for KRAS Mutation Detection (PEAKRAS)

  Universiteit Antwerpen· Antwerpen, Belgium· EU contribution €216,240· until Jan 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  KRAS Targeting in Oncogenic Systems: reconstructing the KRAS signalling network to identify optimal drug combinations (KRATOS)

  University College Dublin, National University of Ireland, Dublin· Dublin, Ireland· EU contribution €426,534· until Jan 2030· 2 countries

  The disease is named only in the funder's project summary, not in the title.

5 of 66 running projects, newest first. Listed amounts together: €224.7m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures

  NCT06713798· Gustave Roussy, Cancer Campus, Grand Paris· Updated 23 Mar 2026

  “Roche stopped thr peoduction of one of the study product.”Registry text, quoted unchanged. Source

• Terminated

  Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

  NCT04585815· Pfizer· Updated 9 Jan 2026

  “Study was terminated due to portfolio re-prioritization and strategic considerations. The decision was not based on any safety concerns and/or regulatory interactions”Registry text, quoted unchanged. Source

• Terminated

  Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors

  NCT05757492· Coherus Oncology, Inc.· Updated 1 May 2025

  “The study was terminated for strategic reasons (not for safety concerns)”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

  NCT04995523· AstraZeneca· Source

• A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

  NCT06692738· AstraZeneca· Source

• A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

  NCT06627647· AstraZeneca· Source

• A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

  NCT06996782· AstraZeneca· Source

• A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

  NCT07098338· AstraZeneca· Source

• A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

  NCT06868277· AstraZeneca· Source

• A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT03563716· Genentech, Inc.· Source

• Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

  NCT04585815· Pfizer· Source

• Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

  NCT05014815· BeiGene· Source

• Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

  NCT03739710· GlaxoSmithKline· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 145
• Organoids 47
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 43
• Gene Expression Profiling 314
• Sequence Analysis, RNA 43
• Whole Genome Sequencing 13
• Exome Sequencing 18
• Proteomics 133
• Metabolomics 67
• Mass Spectrometry 25
• Flow Cytometry 73
• Immunohistochemistry 191
• Liquid Biopsy 76
• Circulating Tumor DNA 83
• Xenograft Model Antitumor Assays 617
• Positron-Emission Tomography 70
• Magnetic Resonance Imaging 116
• Machine Learning 290
• Deep Learning 211
• Cohort Studies 289
• Genome-Wide Association Study 75

• Integrated Whole-Genome and RNA Sequencing Analysis of FFPE Lung Cancer Samples: Feasibility and Pathological Validation.

  Pathol Int, Nov 2026

• Network-informed deconvolution of bulk immune gene co-expression reveals single-cell programs and spatial organization.

  Front Immunol, Sept 2026

• 5' Rapid Amplification of cDNA Ends (5' RACE)-Based Targeted RNA Sequencing Assay for the Analysis of Clinically Relevant Alterations in Lung Cancer Patients.

  Int J Mol Sci, Aug 2026

• Regulatory effects of smoking cessation on the cellular microenvironment and differentially expressed genes in precancerous lesions of pulmonary nodules in mice based on single-cell RNA sequencing and immune repertoire-sequencing.

  PLoS One, Aug 2026

• DeMixNB: deconvolution of sparse-count RNA sequencing data for tumor cells using embedded negative binomial distributions.

  Genome Biol, Aug 2026

• A Rho GTPase-related gene signature predicts prognosis and reveals an immunosuppressive microenvironment in lung adenocarcinoma: an integrated analysis of bulk and single-cell RNA sequencing data.

  Sci Rep, Jul 2026

• PLNFGL: joint estimation of multi-condition gene networks from single-cell RNA-seq data.

  Bioinformatics, Jul 2026

• Unveiling tumor heterogeneity by single cell RNA-sequencing: From basic considerations to clinical applications.

  Semin Cancer Biol, Jun 2026

• ScQCenrich enables multi-metric quality control for single-cell RNA sequencing.

  Commun Biol, Jun 2026

• Single cell RNA-sequencing meta-analysis identifies the molecular signature of smoking cessation on the human lung.

  Transl Res, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.